SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S ENOXAPARIN SODIUM INJECTION OBTAINS APPROVAL FROM HEALTH CANADA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**", together with its subsidiaries referred to as the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Shenzhen Techdow Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, has received the Marketing Authorisation from Health Canada for Redesca and Redesca HP, the Group's drug brands of enoxaparin sodium injection.

DETAILS OF THE DRUG

(I) Drug brand: Redesca and Redesca HP

(II) REDESCA (enoxaparin) is indicated for:

The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing:

- orthopedic surgery of the hip or knee; In addition, REDESCA is indicated in hospital or after hospital discharge for long-term prevention of venous thromboembolic diseases following hip replacement surgery.
- high risk abdominal, gynecological, or urological surgeries
- colorectal surgery

The prophylaxis of deep vein thrombosis (DVT) in medical patients who are at moderate risk of DVT and who are bedridden due to moderate to severe acute cardiac insufficiency (NYHA

Class III or IV heart failure), acute respiratory failure revealing or complicating chronic respiratory insufficiency not requiring ventilatory support and acute respiratory infections (excluding septic shock), who require short-term prophylaxis of deep vein thrombosis.

The prevention of thrombus formation in the extra-corporeal circulation during hemodialysis.

REDESCA is also indicated for:

The treatment of deep vein thrombosis, with or without pulmonary embolism.

The treatment of unstable angina or non-Q-wave myocardial infarction, concurrently with ASA.

Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI), including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).

(III) Dosage form: Solution for injection

(IV) Strength:
Redesca: 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1.0mL, 120mg/0.8mL, 150mg/1.0mL and 30mg/3mL
Redesca HP: 120mg/0.8mL and 150mg/1.0mL

(V) Registration Category: Prescription drug

BENEFITS AND IMPACTS TO THE COMPANY

The enoxaparin sodium injection products of the Group have been approved in a total of 37 countries including Canada and sold in 21 countries. Meanwhile, the Group also can supply enoxaparin sodium injection to its customers in 15 other countries. The Board believes that the Group's enoxaparin sodium injection products have been granted approval by the United States, Saudi Arabia and China successively in 2020, and this approval from Canada has further enhanced the Group's market layout in North America, which will further accelerate the implementation of the Group's global strategic expansion in order to become a leading pharmaceutical company in the world.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
December 9, 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.